Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the company's Alinity m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) in one test. This is an important tool because these viruses have similar symptoms but require different treatment approaches.
I wonder when they submitted this for FDA approval and how that compares to when CODX submitted. I am trying to guess when we can expect approval.
Co-Diagnostics: A+ Student Faces New Tests Mar. 12, 2021 10:45 AM ETCo-Diagnostics, Inc. (CODX)3 Likes Summary Co-Diagnostics went public in 2017 with a proprietary infectious disease testing technology and a clever strategy. During its early rollout, Co-Diagnostics' strategy failed to generate noticeable revenues. As 2020 unfolded, the pandemic both validated Co-Diagnostics' technology and its revenue potential. Surprisingly, Co-Diagnostics is maintaining its appeal even as the pandemic starts to wind down. I first became interested in Co-Diagnostics (CODX) because of its outstanding A+ quant grades for value, growth, and profitability on 12/22/20. These grades set it apart from its Healthcare peers; only two others were able to match its report.
Recently I checked back to see how it was faring. As I write on 3/11/21 its report is holding strong, A+'s across all three terrains as shown below:
Co-Diagnostics In this article I will drill down on Co-Diagnostics, explaining why I agree from an operational standpoint with its stellar quant grades. I take an optimistic view of its prospects. Those who have room in their portfolio for a highly speculative micro-cap with good prospects should find that Co-Diagnostics just fills the bill.
News 
Market Data 
Discover 
